Clinical Trials Logo

HRAS Mutant Tumor clinical trials

View clinical trials related to HRAS Mutant Tumor.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02383927 Completed - Thyroid Cancer Clinical Trials

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Start date: March 2015
Phase: Phase 2
Study type: Interventional

Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available. Note; Only cohort 2 (Head & Neck SCC) and cohort 3 (Other SCC) are currently open